1. Home
  2. PRPL vs SKYE Comparison

PRPL vs SKYE Comparison

Compare PRPL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPL
  • SKYE
  • Stock Information
  • Founded
  • PRPL 2010
  • SKYE 2012
  • Country
  • PRPL United States
  • SKYE United States
  • Employees
  • PRPL N/A
  • SKYE N/A
  • Industry
  • PRPL Home Furnishings
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRPL Consumer Discretionary
  • SKYE Health Care
  • Exchange
  • PRPL Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • PRPL 90.3M
  • SKYE 80.7M
  • IPO Year
  • PRPL N/A
  • SKYE N/A
  • Fundamental
  • Price
  • PRPL $1.03
  • SKYE $3.13
  • Analyst Decision
  • PRPL Buy
  • SKYE Buy
  • Analyst Count
  • PRPL 3
  • SKYE 6
  • Target Price
  • PRPL $1.70
  • SKYE $18.67
  • AVG Volume (30 Days)
  • PRPL 581.0K
  • SKYE 217.3K
  • Earning Date
  • PRPL 03-11-2025
  • SKYE 02-25-2025
  • Dividend Yield
  • PRPL N/A
  • SKYE N/A
  • EPS Growth
  • PRPL N/A
  • SKYE N/A
  • EPS
  • PRPL N/A
  • SKYE N/A
  • Revenue
  • PRPL $504,838,000.00
  • SKYE N/A
  • Revenue This Year
  • PRPL N/A
  • SKYE N/A
  • Revenue Next Year
  • PRPL $1.83
  • SKYE N/A
  • P/E Ratio
  • PRPL N/A
  • SKYE N/A
  • Revenue Growth
  • PRPL N/A
  • SKYE N/A
  • 52 Week Low
  • PRPL $0.75
  • SKYE $2.31
  • 52 Week High
  • PRPL $2.33
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • PRPL 47.18
  • SKYE 51.55
  • Support Level
  • PRPL $0.99
  • SKYE $2.60
  • Resistance Level
  • PRPL $1.09
  • SKYE $3.54
  • Average True Range (ATR)
  • PRPL 0.07
  • SKYE 0.50
  • MACD
  • PRPL -0.02
  • SKYE 0.03
  • Stochastic Oscillator
  • PRPL 13.21
  • SKYE 30.91

About PRPL Purple Innovation Inc.

Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: